Increased osteoclast development after estrogen loss: mediation by interleukin-6.
Level 5 - mechanism / opinion, no new human data
Preclinical animal (ovariectomized mice) and in vitro/ex vivo cell culture study
PubMed 1621100 · doi:10.1126/science.1621100
What was done
Researchers examined the regulation of interleukin-6 (IL-6) and osteoclastogenesis by estrogen. In vitro, bone and marrow stromal cells were treated with 17 beta-estradiol to assess IL-6 production. In mice, estrogen deficiency was induced via ovariectomy, and researchers measured colony-forming units for granulocytes and macrophages, ex vivo marrow osteoclast development, and osteoclast counts in trabecular bone, with or without 17 beta-estradiol or an anti-IL-6 antibody.
What was found
17 beta-estradiol suppressed IL-6 production by bone and marrow stromal cells in vitro. Ovariectomy in mice increased granulocyte-macrophage colony-forming units, marrow osteoclast development, and trabecular bone osteoclast counts; all of these increases were prevented by administration of 17 beta-estradiol or an antibody to IL-6. No numerical values, effect sizes, or statistical metrics were provided in the abstract.
Why it matters
This work identifies IL-6 as a functional mediator between estrogen loss and accelerated osteoclastogenesis, offering a mechanistic basis for bone loss in postmenopausal osteoporosis.
Limits
The findings are limited to animal and cell culture models, which may not directly translate to human disease. The abstract provides no sample sizes, numerical data, effect magnitudes, or statistical confidence measures. Long-term skeletal endpoints like bone mineral density or fracture rates were not reported.
Cited by
- supports Estrogen loss induces interleukin-6 (IL-6), which promotes the development of osteoporosis.